Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models

PURPOSE: Radium-223 dichloride (radium-223, Xofigo®), a targeted alpha therapy, is currently used for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases. This study examines the mode-of-action and antitumor efficacy of radium-223 in two prostate cancer xe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Suominen, Mari I., Fagerlund, Katja M., Rissanen, Jukka P., Konkol, Yvonne M., Morko, Jukka P., Peng, ZhiQi, Alhoniemi, Esa J., Laine, Salla K., Corey, Eva, Mumberg, Dominik, Ziegelbauer, Karl, Käkönen, Sanna-Maria, Halleen, Jussi M., Vessella, Robert L., Scholz, Arne
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540794/
https://ncbi.nlm.nih.gov/pubmed/28364014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2955
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky